Multiplex Assay Kit for Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay)

VEGF-B; VEGFL; VRF; VEGF-Related Factor

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 94-103 101
EDTA plasma(n=5) 84-103 98
heparin plasma(n=5) 99-105 102

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 92-99% 91-104% 93-101% 96-105%
EDTA plasma(n=5) 80-92% 84-101% 90-102% 81-96%
heparin plasma(n=5) 79-97% 90-104% 98-105% 80-97%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:VEGFB) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
International Journal of Cardiology Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. PubMed: 22459379
Applied Sciences-Basel Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study pubmed:29099033
Journal of Endocrinological Investigation Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell 10.1007/s40618-017-0677-z
EXCLI Journal Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction
Cancer Chemother Pharmacol Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors 34164713
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA144Hu01 Recombinant Vascular Endothelial Growth Factor B (VEGFB) Positive Control; Immunogen; SDS-PAGE; WB.
APA144Hu01 Active Vascular Endothelial Growth Factor B (VEGFB) Cell culture; Activity Assays.
PAA144Hu01 Polyclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB) WB; IHC; ICC; IP.
LAA144Hu71 Biotin-Linked Polyclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB) WB; IHC; ICC.
LAA144Hu81 FITC-Linked Polyclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB) WB; IHC; ICC; IF.
MAA144Hu22 Monoclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB) WB; IHC; ICC; IP.
LAA144Hu82 FITC-Linked Monoclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB) WB; IHC; ICC; IF.
LAA144Hu72 Biotin-Linked Monoclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB) WB; IHC; ICC.
SEA144Hu ELISA Kit for Vascular Endothelial Growth Factor B (VEGFB) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA144Hu Multiplex Assay Kit for Vascular Endothelial Growth Factor B (VEGFB) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.